Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12605000765628
Ethics application status
Approved
Date submitted
22/11/2005
Date registered
25/11/2005
Date last updated
10/01/2017
Type of registration
Prospectively registered
Titles & IDs
Public title
A randomised clinical trial of different infusion rates of magnesium sulphate given prenatally to women.
Query!
Scientific title
A randomised clinical trial of different infusion rates of magnesium sulphate given prenatally to women for the prevention of side effects.
Query!
Secondary ID [1]
282063
0
Nil known.
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Magnesium sulphate therapy, prior to very preterm birth.
921
0
Query!
Condition category
Condition code
Reproductive Health and Childbirth
988
988
0
0
Query!
Fetal medicine and complications of pregnancy
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Women recruited will receive a magnesium sulphate intravenous infusion for 24 hours or until they give birth (whichever is the shorter) and will be randomised to different rates of administration of the intravenous loading infusion. 4 g magnesium sulphate over 60 minutes followed by 1 g per hour versus 4 g magnesium sulphate over 20 minutes followed by 1 g per hour.
Query!
Intervention code [1]
770
0
Treatment: Drugs
Query!
Comparator / control treatment
Active control: 4 g magnesium sulphate administered over 20 minutes followed by 1 g per hour for 24 hours or until birth (whichever is the shorter).
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
1311
0
Occurrence of any maternal adverse effects (clinical and self-assessed) during the magnesium sulphate infusion. This includes: arm discomfort with infusion, blurred vision, confusion/drowsiness, dizziness, headache, mild nausea/vomiting, mouth dryness, muscle weakness, palpitations, sweating, warmth/flushing, other reported side effects, tachycardia, respiratory depression.
Query!
Assessment method [1]
1311
0
Query!
Timepoint [1]
1311
0
Measured at 20 minutes and 60 minutes after the start of the infusion, and at completion of the infusion.
Query!
Secondary outcome [1]
2349
0
Magnesium concentrations in cord blood at birth for the infant.
Query!
Assessment method [1]
2349
0
Query!
Timepoint [1]
2349
0
Measured at birth.
Query!
Secondary outcome [2]
2350
0
Total amount of magnesium sulphate given prior to birth
Query!
Assessment method [2]
2350
0
Query!
Timepoint [2]
2350
0
Measured prior to birth.
Query!
Secondary outcome [3]
301552
0
Cessation of treatment due to adverse effects attributed to the magnesium sulphate infusion.
Query!
Assessment method [3]
301552
0
Query!
Timepoint [3]
301552
0
Measured throughout the infusion.
Query!
Secondary outcome [4]
301553
0
Adverse cardiorespiratory effects of the infusion (defined as a respiratory rate <16/minute, sdrop in diastolic blood pressure >15mmHg, cardiac arrest, respiratory arrest, maternal death)
Query!
Assessment method [4]
301553
0
Query!
Timepoint [4]
301553
0
Measured at 20 minutes and 60 minutes after the start of the infusion, and at completion of the infusion.
Query!
Eligibility
Key inclusion criteria
Women who are now recommended magnesium sulphate as per the National Clinical Practice Guidelines, and the South Australian Perinatal Practice Guidelines: a gestational age of less than 30 weeks where birth is planned or definitely expected within 24 hours. The women must have a singleton or twin pregnancy.
Query!
Minimum age
Not stated
Query!
Query!
Maximum age
Not stated
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1) Women with the following contraindications to magnesium sulphate: absent patellar reflexes, hypocalcaemia, respiratory rate < 16/minute, renal failure, urine output < 100mls during the last 4 hours;
2) Women who are in the second stage of labour;
3) Women who have already been given magnesium sulphate therapy in this pregnancy.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central telephone randomisation service
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer-generated random number sequence
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
1/01/2006
Query!
Actual
21/02/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
3/04/2012
Query!
Date of last data collection
Anticipated
Query!
Actual
30/06/2012
Query!
Sample size
Target
51
Query!
Accrual to date
Query!
Final
51
Query!
Recruitment in Australia
Recruitment state(s)
SA
Query!
Funding & Sponsors
Funding source category [1]
1085
0
University
Query!
Name [1]
1085
0
ARCH: Australian Research Centre for Health of Women and Babies, The Robinson Institute, The University of Adelaide
Query!
Address [1]
1085
0
Level 1, Queen Victoria Building,
Women's and Children's Hospital,
72 King William Street,
NORTH ADELAIDE SA 5006
Query!
Country [1]
1085
0
Australia
Query!
Primary sponsor type
University
Query!
Name
ARCH: Australian Research Centre for Health of Women and Babies, The Robinson Institute, The University of Adelaide
Query!
Address
Level 1, Queen Victoria Building,
Women's and Children's Hospital,
72 King William Street,
NORTH ADELAIDE SA 5006
Query!
Country
Australia
Query!
Secondary sponsor category [1]
946
0
None
Query!
Name [1]
946
0
N/A
Query!
Address [1]
946
0
Query!
Country [1]
946
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
2389
0
Children, Youth and Women’s Health Services Human Research Ethics Committee
Query!
Ethics committee address [1]
2389
0
Adelaide, South Australia
Query!
Ethics committee country [1]
2389
0
Australia
Query!
Date submitted for ethics approval [1]
2389
0
Query!
Approval date [1]
2389
0
01/11/2005
Query!
Ethics approval number [1]
2389
0
1651/2/2013
Query!
Summary
Brief summary
This randomised clinical trial will assess whether a slower, compared with the standard infusion rate of the loading dose of magnesium sulphate, given to women at risk of very preterm birth at less than 30 weeks gestation for fetal neuroprotection, is effective in reducing maternal adverse effects of treatment.
Query!
Trial website
Query!
Trial related presentations / publications
Maternal adverse effects with different loading infusion rates of antenatal magnesium sulphate for preterm fetal neuroprotection: the IRIS randomised trial. Bain ES, Middleton PF, Yelland LN, Ashwood PJ, Crowther CA. BJOG. 2014 Apr;121(5):595-603. doi: 10.1111/1471-0528.12535.
Query!
Public notes
Query!
Attachments [1]
1350
1350
0
0
/AnzctrAttachments/905-Bain_et_al-2014-BJOG-_An_International_Journal_of_Obstetrics_&_Gynaecology.pdf
Query!
Query!
Contacts
Principal investigator
Name
36340
0
Prof Caroline Crowther
Query!
Address
36340
0
ARCH: Australian Research Centre for Health of Women and Babies,
The Robinson Institute,
Discipline of Obstetrics and Gynaecology,
School of Paediatrics and Reproductive Health,
The University of Adelaide,
Level 1, Queen Victoria Building,
Women's and Children's Hospital,
72 King William Street,
NORTH ADELAIDE SA 5006
Query!
Country
36340
0
Australia
Query!
Phone
36340
0
+61 8 81617647
Query!
Fax
36340
0
Query!
Email
36340
0
[email protected]
Query!
Contact person for public queries
Name
9959
0
Caroline Crowther
Query!
Address
9959
0
ARCH: Australian Research Centre for Health of Women and Babies,
The Robinson Institute,
Discipline of Obstetrics and Gynaecology,
School of Paediatrics and Reproductive Health,
The University of Adelaide,
Level 1, Queen Victoria Building,
Women's and Children's Hospital,
72 King William Street,
NORTH ADELAIDE SA 5006
Query!
Country
9959
0
Australia
Query!
Phone
9959
0
+61 8 81617647
Query!
Fax
9959
0
+61 8 81617652
Query!
Email
9959
0
[email protected]
Query!
Contact person for scientific queries
Name
887
0
Caroline Crowther
Query!
Address
887
0
ARCH: Australian Research Centre for Health of Women and Babies,
The Robinson Institute,
Discipline of Obstetrics and Gynaecology,
School of Paediatrics and Reproductive Health,
The University of Adelaide,
Level 1, Queen Victoria Building,
Women's and Children's Hospital,
72 King William Street,
NORTH ADELAIDE SA 5006
Query!
Country
887
0
Australia
Query!
Phone
887
0
+61 8 81617647
Query!
Fax
887
0
+61 8 81617652
Query!
Email
887
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF